Ballesta AM - Search Results

1

Serum levels of beta2-microglobulin, neopterin, TNF-alpha and soluble receptors of TNF-alpha and interleukin-2 in intravenous drug abusers according to HIV-1 status and stage of the HIV-1 infection.

Bedini JL, García F, Miró JM, Aznar E, Serrano J, Lozano L, Mallolas J, Filella X, Vidal J, Latorre X, Gatell JM, Ballesta AM, Soriano E. Bedini JL, et al. Among authors: ballesta am. Clin Microbiol Infect. 1998 Jan;4(1):4-10. doi: 10.1111/j.1469-0691.1998.tb00327.x. Clin Microbiol Infect. 1998. PMID: 11864226 Free article.

2

Pro-gastrin-releasing peptide in patients with benign and malignant diseases.

Molina R, Auge JM, Alicarte J, Filella X, Viñolas N, Ballesta AM. Molina R, et al. Among authors: ballesta am. Tumour Biol. 2004 Jan-Apr;25(1-2):56-61. doi: 10.1159/000077724. Tumour Biol. 2004. PMID: 15192313

3

Complexed prostate-specific antigen for the detection of prostate cancer.

Filella X, Truan D, Alcover J, Gutierrez R, Molina R, Coca F, Ballesta AM. Filella X, et al. Among authors: ballesta am. Anticancer Res. 2004 Nov-Dec;24(6):4181-5. Anticancer Res. 2004. PMID: 15736470 Free article.

4

Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.

Filella X, Truan D, Alcover J, Quintó L, Molina R, Luque P, Coca F, Ballesta AM. Filella X, et al. Among authors: ballesta am. Urology. 2004 Jun;63(6):1100-3; discussion 1103-4. doi: 10.1016/j.urology.2004.01.056. Urology. 2004. PMID: 15183958 Clinical Trial.

5

Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.

Molina R, Auge JM, Filella X, Viñolas N, Alicarte J, Domingo JM, Ballesta AM. Molina R, et al. Among authors: ballesta am. Anticancer Res. 2005 May-Jun;25(3A):1773-8. Anticancer Res. 2005. PMID: 16033098 Free article.

6

Relationship of p53 with other oncogenes, cytokines and systemic lupus erythematosus activity.

Miret C, Molina R, Filella X, García-Carrasco M, Claver G, Ingelmo M, Ballesta A, Font J. Miret C, et al. Tumour Biol. 2003 Aug-Sep;24(4):185-8. doi: 10.1159/000074428. Tumour Biol. 2003. PMID: 14654712

7

[Usefulness of PSA and its fractions in the diagnosis of prostate cancer].

Filella X, Truan D, Alcover J, Molina R, Luque P, Coca F, Ballesta AM. Filella X, et al. Among authors: ballesta am. Med Clin (Barc). 2004 Feb 28;122(7):241-4. doi: 10.1016/s0025-7753(04)75311-7. Med Clin (Barc). 2004. PMID: 15012870 Spanish.

8

Tobramycin and amikacin nephrotoxicity. Value of serum creatinine versus urinary concentration of beta-2-microglobulin.

Gatell JM, SanMiguel JG, Zamora L, Araujo V, Castells C, Moreno A, Jimenez de Anta MT, Marin JL, Elena M, Ballesta A. Gatell JM, et al. Nephron. 1985;41(4):337-43. doi: 10.1159/000183611. Nephron. 1985. PMID: 3906418 Clinical Trial.

9

Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin.

Gatell JM, San Miguel JG, Zamora L, Araujo V, Bonet M, Bohé M, Jimenez de Anta MT, Farré M, Elena M, Ballesta A, Marin JL. Gatell JM, et al. Antimicrob Agents Chemother. 1983 Jun;23(6):897-901. doi: 10.1128/AAC.23.6.897. Antimicrob Agents Chemother. 1983. PMID: 6614894 Free PMC article. Clinical Trial.

10

Lower specific micronutrient intake in colorectal cancer patients with tumors presenting promoter hypermethylation in p16(INK4a), p4(ARF) and hMLH1.

Mas S, Lafuente MJ, Crescenti A, Trias M, Ballesta A, Molina R, Zheng S, Wiencke JK, Lafuente A. Mas S, et al. Anticancer Res. 2007 Mar-Apr;27(2):1151-6. Anticancer Res. 2007. PMID: 17465256 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

123 results

Search Page

Filters